Baron Discovery Fund (BDFFX)

Portfolio Management

Randolph Gwirtzman

Fund Manager since 2013

View All Commentary by Randolph LairdBieger
Laird Bieger

Fund Manager since 2013

View All Commentary by Laird

Fund Description

Baron Discovery Fund invests primarily in small growth companies.

Fund Resources

Latest Fact Sheets

Standard Fact Sheet


Portfolio Commentary

Retail Performance

Review and Outlook (for quarter ended 9/30/2015)

U.S. stock markets were unusually volatile during the three months ended September 30, 2015. Most indexes fell sharply, with small caps performing worse than large and mid cap stocks. The small cap Russell 2000 Growth Index lost 13.06% in the third quarter.

Baron Discovery Fund declined by 19.80% in the third quarter. Materials was the only sector to contribute to performance. Health Care, Information Technology (IT), and Industrials were the largest detracting sectors in the quarter. Materials gained on an increase in the share price of Flotek Industries, Inc., which was the Fund’s top contributor in the quarter. The Health Care sector experienced a broad-based decline late in the quarter, led by the health care supplies and biotech sub-industries. Biotech plunged after Hillary Clinton released a proposal to lower drug costs. Comments from the Federal Reserve suggesting it would raise interest rates by year end and concerns over possible cuts or delays in government spending on health care also negatively impacted the sector. IT also experienced a broad-based decline as investors exited high-growth, high-multiple stocks for more defensive sectors and asset classes. The decline of the Industrials sector was led by the third biggest detractor from performance, CaesarStone Sdot-Yam Ltd.

We continue to see a choppy macro environment which is something we have been calling out since Q3 of last year.  While we had hoped to see more improvement in the economy by this point, the reality is that the economic data has not meaningfully improved. That being said, while we are mindful of the macro-economic landscape, we are primarily driven by the prospects of the individual companies that we own in the portfolio. On that front, we remain more upbeat based on the conversations we have had with our companies. We believe that many of our companies have the potential to grow through  economic choppiness.

While the year-to-date performance has been disappointing, we continue to stay focused on “discovering” the next great growth company. We do not think that the more recent performance of the Fund is indicative of our potential to accomplish that goal over the longer term.

Top Contributors/Detractors to Performance

Contributors (for quarter ended 9/30/2015)
  • Flotek Industries, Inc. supplies chemical additives to the oil & gas industry. Flotek has a proprietary product that is proving to be extremely effective at increasing oil & gas shale well productivity. Shares rebounded sharply in Q3 following much stronger-than-expected Q2 results, principally driven by stronger-than-expected sales and margins. Complex nano-Fluid technology sales growth is outpacing industry activity levels by a wide margin as customers seek to optimize production in the most capitally efficient manner. Flotek’s strategy of marketing and selling its core product directly to end-users is also gaining traction.

  • Neos Therapeutics, Inc. is a pharmaceutical company developing oral dissolving, extended release versions of ADHD medications. The company had its IPO in the quarter, and shares rose on the strength of excitement around planned 2016 launches.

  • Shares of Chuy’s Holdings, Inc., owner and operator of the Chuy’s casual dining restaurant chain, were up in Q3. Better-than-expected Q2 operating results demonstrated that the company’s unit growth efforts are back on track after a few new markets underperformed expectations last year, driving up the stock price. We sold our position after the stock’s rally, which had brought the shares up to our price target.

Detractors (for quarter ended 9/30/2015)
  • The Spectranetics Corporation manufacturers medical devices that clear plaque from arteries. It missed revenues in Q1 due to softness in a smaller product segment (cutting balloons), and lowered full year guidance as a result. In July, it lowered full year revenue guidance again due to competition affecting cutting balloons and lower growth in its lead products. Shares fell in Q3 as a result. We believe the market has misunderstood some of the dynamics, and the share price reflects a true worst case scenario.

  • Shares of breast implant company Sientra, Inc. fell sharply following its announcement in early September that its contract manufacturer had contamination issues, causing EU authorities to shut production to Europe for non-Sientra products. We grew concerned since Sientra products are made on the same lines, and sold our position at a loss. In late September, after we exited, U.S. production of Sientra products was halted as well. Although painful, we believe we reacted correctly as the shutdown can potentially cause significant damage to the company.

  • CaesarStone Sdot-Yam Ltd. is a leading global manufacturer of quartz surfaces for kitchens and bathrooms. Shares fell sharply in August after the company reduced its full-year revenue guidance on the second quarter earnings call. A negative report by a short seller of the stock also weighed on the stock price. We believe investors overreacted to both events and remain positive on our investment in CaesarStone, as earnings growth accelerates from successful new product launches and quartz market share gains vs. other countertop materials.

Quarterly Attribution Analysis (for quarter ended 9/30/2015)

The Quarterly Attribution Analysis for period ending September 30, 2015 is not yet available

Back to Top

Invest In Baron Funds Today

The prospective performance of the companies discussed herein is based on our internal analysis and reflect our opinions only. We cannot promise future returns and our opinions are a reflection of our best judgement at the time of publication. Our views are not intended as recommendations or investment advise to any person and are subject to chage at any time based on market and other conditions and Baron has no obligation to update them. Investing in the stock market is always risky. Current and future portfolio holdings in the Fund are subject to risk.

Source: FactSet PA.